[go: up one dir, main page]

PE20080935A1 - THERAPY USING CYTOKINE INHIBITORS - Google Patents

THERAPY USING CYTOKINE INHIBITORS

Info

Publication number
PE20080935A1
PE20080935A1 PE2007000714A PE2007000714A PE20080935A1 PE 20080935 A1 PE20080935 A1 PE 20080935A1 PE 2007000714 A PE2007000714 A PE 2007000714A PE 2007000714 A PE2007000714 A PE 2007000714A PE 20080935 A1 PE20080935 A1 PE 20080935A1
Authority
PE
Peru
Prior art keywords
ter
tolil
butil
members
saturated
Prior art date
Application number
PE2007000714A
Other languages
Spanish (es)
Inventor
Constance A Crowley
Nancy G J Delaet
Justin Ernst
Carrie Gail Grove
Bonnie Hepburn
Bernard King
Christopher J Larson
Stephen Miller
Kent Pryor
Lewis J Shuster
Original Assignee
Kemia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemia Inc filed Critical Kemia Inc
Publication of PE20080935A1 publication Critical patent/PE20080935A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN METODO PARA TRATAR UN TRASTORNO POR UNA O MAS CITOCINAS QUE COMPRENDE EN ADMINISTRAR UN COMPUESTO DE FORMULAS: IA, IB, IC, II, III y IV; ENTRE OTROS; SOLOS O EN COMBINACION; EN DONDE G ES UN CARBOCICLILO(C3-C10), HETEROCICLILO MONOCICLILO DE 5 A 8 MIEMBROS O HETEROCICLILO BICICLICO DE 8 A 11 MIEMBROS; X ES C(O), C(S) O CH2; Ar ES DIOXIDO DE INDAZOLILO, INDOLILO, IMIDAZOLILO, PIRAZOLILO, ENTRE OTROS; L ES UN ENLACE COVALENTE O UNA CADENA DE CARBONO(C1-C10) SATURADA O NO SATURADA; Q ES H, CICLOALQUILO, ARILO, ALCOXI DE C1-C6, ENTRE OTROS. SON SELECCIONADOS: (5-TER-BUTIL-2-p-TOLIL-2H-PIRAZOL-3-IL)-AMIDA DEL ACIDO 1H-INDAZOL-3-CARBOXILICO, 3-TER-BUTIL-5-FENIL-1-p-TOLIL-1,6-DIHIDRO-IMIDAZO[4,5-c]PIRAZOL, N-(5-TER-BUTIL-3-METANSULFONILAMINO-2-METOXI-FENIL)-2-[4-(2-MORFOLIN-4-IL-PIRIMIDIN-4-ILOXI)-NALTALEN-1-IL]-2-OXO-ACETAMIDA. TAMBIEN SE FERIERE A UNA COMPOSICION FARMACEUTICA. SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES, INFLAMATORIAS, CARDIOVASCULARES Y CANCERREFERS TO A METHOD TO TREAT A DISORDER DUE TO ONE OR MORE CYTOKINES THAT INCLUDES ADMINISTERING A COMPOUND OF FORMULAS: IA, IB, IC, II, III and IV; AMONG OTHERS; ALONE OR IN COMBINATION; WHERE G IS A CARBOCYCLYL (C3-C10), HETEROCYCLYL MONOCYCLYL OF 5 TO 8 MEMBERS OR BICYCLE HETEROCYCLE OF 8 TO 11 MEMBERS; X IS C (O), C (S) O CH2; Ar IS DIOXIDE OF INDAZOLYL, INDOLYL, IMIDAZOLYL, PYRAZOLIL, AMONG OTHERS; L IS A COVALENT LINK OR A SATURATED OR NON-SATURATED CARBON (C1-C10) CHAIN; Q IS H, CYCLOALKYL, ARYL, C1-C6 ALCOXY, AMONG OTHERS. THEY ARE SELECTED: (5-TER-BUTIL-2-p-TOLIL-2H-PIRAZOL-3-IL) -AMIDE OF 1H-INDAZOL-3-CARBOXYL ACID, 3-TER-BUTIL-5-FENIL-1-p- TOLIL-1,6-DIHYDRO-IMIDAZO [4,5-c] PYRAZOLE, N- (5-TER-BUTYL-3-METANSULPHONYLAMINO-2-METHYL-PHENYL) -2- [4- (2-MORFOLIN-4- IL-PYRIMIDIN-4-ILOXI) -NALTALEN-1-IL] -2-OXO-ACETAMIDE. IT ALSO CONFIRMS A PHARMACEUTICAL COMPOSITION. BEING USEFUL IN THE TREATMENT OF AUTOIMMUNE, INFLAMMATORY, CARDIOVASCULAR AND CANCER DISEASES

PE2007000714A 2006-06-09 2007-06-08 THERAPY USING CYTOKINE INHIBITORS PE20080935A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81226806P 2006-06-09 2006-06-09
US83307806P 2006-07-24 2006-07-24
US83527006P 2006-08-03 2006-08-03

Publications (1)

Publication Number Publication Date
PE20080935A1 true PE20080935A1 (en) 2008-08-02

Family

ID=38832677

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000714A PE20080935A1 (en) 2006-06-09 2007-06-08 THERAPY USING CYTOKINE INHIBITORS

Country Status (8)

Country Link
EP (1) EP2035005A4 (en)
AR (1) AR061273A1 (en)
AU (1) AU2007257959A1 (en)
CA (1) CA2691214A1 (en)
CL (1) CL2007001670A1 (en)
PE (1) PE20080935A1 (en)
TW (1) TW200814998A (en)
WO (1) WO2007146712A2 (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1986633B1 (en) 2006-02-10 2014-07-30 Summit Corporation Plc Treatment of duchenne muscular dystrophy
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US7915268B2 (en) 2006-10-04 2011-03-29 Wyeth Llc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
AR063142A1 (en) 2006-10-04 2008-12-30 Pharmacopeia Inc DERIVATIVES OF 2- (BENCIMIDAZOLIL) PURINE AND PURINONES 6-USEFUL SUBSTITUTES AS IMMUNOSUPPRESSORS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
US8440832B2 (en) * 2007-07-13 2013-05-14 Board Of Regents, The University Of Texas System Heterocyclic modulators of cannabinoid receptors
LT2170396T (en) 2007-08-03 2017-03-10 Summit (Oxford) Limited Drug combinations for the treatment of duchenne muscular dystrophy
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
WO2010053861A2 (en) * 2008-11-07 2010-05-14 H. Lundbeck A/S Biologically active amides
WO2010141932A1 (en) 2009-06-05 2010-12-09 Link Medicine Corporation Aminopyrrolidinone derivatives and uses thereof
US20110117055A1 (en) * 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
ES2550033T3 (en) * 2009-12-23 2015-11-04 Ratiopharm Gmbh Ticagrelor solid pharmaceutical dosage form
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
RU2569678C2 (en) 2010-04-22 2015-11-27 Вертекс Фармасьютикалз Инкорпорейтед Method for producing cycloalkylcarboxamido-indole compounds
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
AR081626A1 (en) 2010-04-23 2012-10-10 Cytokinetics Inc AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
PT107894A (en) 2011-10-21 2014-10-31 Abbvie Inc METHODS FOR THE TREATMENT OF HCV COMPREHENDING AT LEAST TWO ANTIVIRAL AGENTS OF DIRECT ACTIVITY, RIBAVIRIN, BUT NOT INTERFERED.
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
ES2702182T3 (en) 2013-03-15 2019-02-27 Verseon Corp Aromatic compounds multisubstituted as serine protease inhibitors
KR102373700B1 (en) 2014-04-02 2022-03-11 인터뮨, 인크. Anti-fibrotic pyridinones
PT3131582T (en) 2014-04-15 2018-10-08 Vertex Pharma Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
BR112017004704A2 (en) 2014-09-17 2018-01-23 Verseon Corp compound, pharmaceutical composition, and method for treating a disease or disorder in an individual
WO2016094688A1 (en) 2014-12-10 2016-06-16 Massachusetts Institute Of Technology Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
SG11201706411YA (en) 2015-02-27 2017-09-28 Verseon Corp Substituted pyrazole compounds as serine protease inhibitors
US10576086B2 (en) 2015-06-12 2020-03-03 University Of Greenwich Triazine derivatives as interferon-gamma inhibitors
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060680T2 (en) 2015-11-19 2023-04-28 Incyte Corp Heterocyclic compounds as immunomodulators
JP6448867B2 (en) 2015-12-15 2019-01-09 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Isoindole compounds
EP3394033B1 (en) 2015-12-22 2020-11-25 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3416950A1 (en) 2016-02-16 2018-12-26 Massachusetts Institute of Technology Max binders as myc modulators and uses thereof
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
TW201808902A (en) 2016-05-26 2018-03-16 美商英塞特公司 Heterocyclic compounds as immunomodulators
AU2017277478B2 (en) * 2016-06-08 2023-03-16 Support-Venture Gmbh Pharmaceutical combinations for treating cancer
MD3472167T2 (en) 2016-06-20 2023-02-28 Incyte Corp Heterocyclic compounds as immunomodulators
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE054548T2 (en) 2016-12-20 2021-09-28 Astrazeneca Ab Aminotriazolopyridine compounds and their use in the treatment of cancer
MA47123A (en) 2016-12-22 2021-03-17 Incyte Corp BENZOOXAZOLE DERIVATIVES AS MMUNOMODULATORS
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
PE20200005A1 (en) 2016-12-22 2020-01-06 Incyte Corp DERIVATIVES OF TETRAHYDRO IMIDAZO [4,5-C] PYRIDINE AS INDUCTORS OF INTERNALIZATION PD-L1
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
MX389668B (en) * 2017-05-15 2025-03-20 Recurium Ip Holdings Llc Analgesic compounds
WO2018229155A1 (en) 2017-06-14 2018-12-20 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
CN107474043A (en) * 2017-09-13 2017-12-15 厦门稀土材料研究所 Nicotinic acid derivatives and their preparation methods and uses
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
PT3691620T (en) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US11667651B2 (en) 2017-12-22 2023-06-06 Hibercell, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
PL4212529T3 (en) 2018-03-30 2025-07-07 Incyte Corporation HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
HRP20230306T1 (en) 2018-05-11 2023-05-12 Incyte Corporation TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS
BR112020024879A2 (en) 2018-06-07 2021-03-09 Idorsia Pharmaceuticals Ltd COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND, METHOD
WO2020056191A1 (en) * 2018-09-13 2020-03-19 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
AU2019387367A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN111825605B (en) * 2019-04-19 2023-03-31 中国科学院上海药物研究所 Aryl ketone amide compound and preparation method and application thereof
TW202112767A (en) 2019-06-17 2021-04-01 美商佩特拉製藥公司 Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
AR119162A1 (en) 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd PYRIDIN-3-YL DERIVATIVES
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
IL291471B2 (en) 2019-09-30 2025-04-01 Incyte Corp Pyrido[3,2-d]pyrimidine compounds as immunomodulators
CN114845709B (en) * 2019-11-05 2024-10-01 德米拉公司 MRGPRX2 antagonists for the treatment of inflammatory disorders
CR20220237A (en) 2019-11-11 2022-08-05 Incyte Corp SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
AR124001A1 (en) 2020-11-06 2023-02-01 Incyte Corp PROCESS FOR MANUFACTURING A PD-1 / PD-L1 INHIBITOR AND SALTS AND CRYSTALLINE FORMS THEREOF
CN113209112B (en) * 2021-02-06 2021-12-24 广州市朝利良生物科技有限公司 Novel coronavirus resistant medicine based on ACE2 and S protein binding target and application thereof
DK4347031T3 (en) 2021-06-04 2025-12-01 Vertex Pharma N-(HYDROXYALKYL-(HETERO)ARYL)-TETRAHYDROFURAN-CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS
WO2023154519A1 (en) 2022-02-14 2023-08-17 Accent Therapeutics, Inc. Inhibitors of rna helicase dhx9 and uses thereof
WO2024059220A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University 6,5 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same
CN118496159B (en) * 2024-07-18 2024-09-24 广州医科大学附属市八医院 Application of compound in preparation of medicine with liver fibrosis preventing and/or treating effect

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004530690A (en) * 2001-05-16 2004-10-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Diaryl urea derivatives useful as anti-inflammatory drugs
WO2005023761A2 (en) * 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors

Also Published As

Publication number Publication date
AR061273A1 (en) 2008-08-13
CA2691214A1 (en) 2007-12-21
WO2007146712A3 (en) 2008-11-27
AU2007257959A1 (en) 2007-12-21
EP2035005A2 (en) 2009-03-18
WO2007146712A2 (en) 2007-12-21
EP2035005A4 (en) 2011-07-06
CL2007001670A1 (en) 2008-01-18
TW200814998A (en) 2008-04-01

Similar Documents

Publication Publication Date Title
PE20080935A1 (en) THERAPY USING CYTOKINE INHIBITORS
EA201100691A1 (en) ANTAGONISTS OF LYSOPHPATIDIC ACID RECEPTORS
EA201170508A1 (en) DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBURONIC ACID
NO20064852L (en) Azaindoles useful as inhibitors of yak and other protein kinases
EA200700118A1 (en) AMIDOCIOUSNESS AND THEIR APPLICATION AS MEDICINES
MX2007005434A (en) Nanoparticulate compositions of tubulin inhibitor.
NO20052888L (en) Diamin triazoles useful as inhibitors of protein kinases
DK1611088T3 (en) Hydroxymates as therapeutic agents
IL181700A0 (en) Quinazoline derivatives and pharmaceutical compositions containing the same
EA200800726A1 (en) INTRODUCTION OF DIPEPTIDYLPEPTIDASE INHIBITORS
EA200700117A1 (en) N-SUBSTITUTED PIPERIDINES AND THEIR APPLICATION AS PHARMACEUTICAL PREPARATIONS
SMT201300096B (en) Prolyl hydroxylase inhibitors
AR060089A1 (en) PAIN TREATMENT
MX384378B (en) THERAPEUTIC DOSAGE OF A NEUROREGULIN OR A SUBSECENCE THEREOF FOR THE TREATMENT OR PROPHYLAXIS OF HEART FAILURE.
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
EA201170351A1 (en) METHODS OF TREATING NEUROPATHIC PAIN
ATE527251T1 (en) BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS
TW200630090A (en) Triazoles useful as inhibitors of protein kinases
MY150599A (en) [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
NZ594067A (en) VISFATIN THERAPEUTIC AGENTS (PEPTIDES, siRNA, FK-866, APO866 ) FOR THE TREATMENT OF ACNE AND OTHER CONDITIONS
EA200702523A1 (en) APPLICATION OF ERYTHROPOIETHIN IN LOW DOSAGE FOR STIMULATION OF ENDOTHELIAL CELLS PRECONDENTS, AND ALSO FOR REGENERATION OF ORGANS AND SLOWING PROGRESSION OF DAMAGES OF FINAL ORGANS
TN2009000213A1 (en) Combination
RU2014139955A (en) SCAN COMBINED THERAPY FOR GLIOBLASTOMA
NO20070502L (en) Azaindoles useful as inhibitors of protein kinases
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes

Legal Events

Date Code Title Description
FX Voluntary withdrawal